Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has issued an update.
Paradigm Biopharmaceuticals Ltd. has issued 97,360,143 new securities, which are options expiring on February 11, 2026, as part of a previously announced transaction. This new issuance indicates Paradigm’s ongoing efforts to enhance its financial position and strategic flexibility in the pharmaceutical sector.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. operates within the pharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company primarily deals with treatments that address unmet medical needs and is listed on the Australian Securities Exchange (ASX).
YTD Price Performance: 16.48%
Average Trading Volume: 3,274
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $121.8M
See more data about PAR stock on TipRanks’ Stock Analysis page.
